Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Amaryl M IR 2/1000 (India vs Turkey) in Fed Healthy Subjects
NCT02395237Phase 1Withdrawn
- Sponsor
- Pharmaceutical Research Unit
- Start
- May 2015
- Primary completion
- May 2015
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of glimepiride and metformin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Pharmaceutical Research Unit. Primary endpoints: Maximum Plasma Concentration and Area Under the Curve to Last Measurable Concentration. Planned start May 2015; status: withdrawn.
02
Drugs
glimepiridemetformin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02395237.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02395237.